SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
SANGAMO THERAPEUTICS, INC
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026
- Market cap
- $39.43M
- P/E (TTM)
- –
- Dividend yield
- –
Sangamo Therapeutics statistics
Financials through Mar 31, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Sangamo Therapeutics | Industry median |
|---|---|---|
| Market Cap | $41.93M | $197.05M |
| Enterprise Value | $14.34M | $106.56M |
| PS Ratio | 1.21 | 3.93 |
Enterprise value
| Measure | Sangamo Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 0.41 | 2.69 |
Income (trailing twelve months)
| Measure | Sangamo Therapeutics | Industry median |
|---|---|---|
| Revenue | $34.56M | $57.94M |
| Operating Income | -$123.56M | -$21.44M |
| Pretax Income | -$124.02M | -$14.45M |
| Net Income | -$123.33M | -$22.46M |
| EBITDA | -$119.90M | -$16.91M |
| EPS (Diluted) | -$0.38 | -$0.83 |
Margins
| Measure | Sangamo Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -357.5% | -44.5% |
| Pretax Margin | -358.9% | -13.0% |
| Profit Margin | -356.9% | -39.2% |
| EBITDA Margin | -347.0% | -31.3% |
| FCF Margin | -261.8% | -8.85% |
Returns
| Measure | Sangamo Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -168.8% | -41.0% |
| Return on Capital Employed (ROCE) | -1808.8% | -37.8% |
Growth
| Measure | Sangamo Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -45.8% | 6.01% |
| Revenue Growth (3Y CAGR) | -29.2% | 2.25% |
| Revenue Growth (5Y CAGR) | -19.7% | 6.42% |
Balance sheet
| Measure | Sangamo Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $27.59M | $62.42M |
| Net Cash (Debt) | $27.59M | $15.68M |
| Net Cash Per Share | $0.07 | $0.65 |
| Equity (Book Value) | -$18.96M | $48.79M |
| Book Value Per Share | -$0.05 | $1.36 |
| Tangible Book Value | -$18.96M | $23.06M |
| Working Capital | -$16.02M | $75.77M |
Financial position
| Measure | Sangamo Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.70 | 3.30 |
| Quick Ratio | 0.54 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Sangamo Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$90.34M | -$12.35M |
| Capital Expenditures | -$115.00K | -$1.06M |
| Free Cash Flow | -$90.46M | -$20.28M |
| FCF Per Share | -$0.22 | -$0.41 |
Efficiency
| Measure | Sangamo Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.47 | 0.38 |
| Revenue Per Employee | $243.36K | $398.96K |
| Profits Per Employee | -$868.52K | -$732.08K |
| Employee Count | 142 | 73 |
Dividends and yields
| Measure | Sangamo Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -294.2% | -21.2% |
| FCF Yield | -215.8% | -7.64% |
| Buyback Yield | -106.9% | -0.58% |
| Shareholder Yield | -106.9% | 0.00% |
Shares
| Measure | Sangamo Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 414,289,000 | 59,128,900 |
| Shares Change (YoY) | 51.9% | 11.1% |
| Float | 409,634,000 | 48,744,500 |
| Shares Held by Insiders | 1.12% | 11.8% |
| Shares Held by Institutions | 0.13% | 59.4% |
Taxes
| Measure | Sangamo Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$687.00K | $91.50K |
Scores
| Measure | Sangamo Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -44.94 | 0.10 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Sangamo Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.